{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:22:36Z","timestamp":1770834156164,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Data on the impact of a heart failure hospitalization (HFH) on outcome in patients with transthyretin cardiac amyloidosis (TTR-CA) are scarce, although it remains a frequent adverse event. To assess the characteristics of patients with HFH in a real-world TTR-CA population, the occurrence of HFH, and the prognosis thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected from a multicentre TTR-CA registry and patients were dichotomized according to the occurrence of at least one HFH. Landmark analysis at the 1-year follow-up and Cox regression analysis with HFH as a time-dependent covariate were performed to assess the impact of HFH on all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 654 patients were included [median age 78 (64, 83) years, 70.5% male, 70.6% wild type]. During a median follow-up of 24 (11\u201345) months, 141 (22%) patients experienced at least one HFH and 170 (26%) patients died. Patients with a HFH were older (82 vs 76 years, P &amp;lt; .001), had more wild-type TTR-CA [126 (89.4%) vs 336 (65.5%), P &amp;lt; .001], were more symptomatic [New York Heart Association Class II\u2013IV 119 (86.9%) vs 279 (62%), P &amp;lt; .001], had higher National Amyloidosis Centre (NAC) disease stage, were less treated with disease-modifying therapy [45 (31.9%) vs 247 (47.4%), P = .001], had more co-morbidities and showed signs of more advanced disease by echocardiography. At the 1-year time point, patients with HFH had significant worse overall survival (log-rank \u03c7\u00b2 37.673, P &amp;lt; .001). At the univariable (HR 7.71, 95%CI 5.50, 10.82; P &amp;lt; .001) and multivariable analyses, HFH was associated with all-cause mortality and showed incremental value on top of clinical variables, biomarkers [estimated glomerular filtration rate in Model 1 (\u03c7\u00b2 97.3; P &amp;lt; .001) and NAC disease stage in Model 2 (\u03c7\u00b2 78.8; P &amp;lt; .001)] and echocardiographic parameters (left ventricular mass index + stroke volume index + significant valvular lesion in Model 3 (\u03c7\u00b2 60.3; P &amp;lt; .001) and including E\/e\u2032 in Model 4 (\u03c7\u00b2 43.4; P &amp;lt; .001)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HFH is independently associated with all-cause mortality in patients with TTR-CA and has incremental value on top of established risk models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvaf013","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:01:39Z","timestamp":1767830499000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-2395","authenticated-orcid":false,"given":"Dorien","family":"Laenens","sequence":"first","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center , Albinusdreef 2, Leiden 2333 ZA ,","place":["Netherlands"]},{"name":"Department of Cardiology, Sint Maarten Hospital , Mechelen ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-3016","authenticated-orcid":false,"given":"Philippe","family":"Debonnaire","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sint Jan Hospital , Bruges ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten A J","family":"De Smet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center , Albinusdreef 2, Leiden 2333 ZA ,","place":["Netherlands"]},{"name":"Department of Cardiology, Sint Jan Hospital , Bruges ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, ULSSM, CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa , Lisboa ,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulce","family":"Brito","sequence":"additional","affiliation":[{"name":"Department of Cardiology, ULSSM, CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa , Lisboa ,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-3249","authenticated-orcid":false,"given":"Steven","family":"Droogmans","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Life Sciences, Vrije Universiteit Brussel , Brussels ,","place":["Belgium"]},{"name":"Department of Cardiology, University Hospital Brussels , Brussels ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik H","family":"Verbrugge","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Life Sciences, Vrije Universiteit Brussel , Brussels ,","place":["Belgium"]},{"name":"Department of Cardiology, University Hospital Brussels , Brussels ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2677-3389","authenticated-orcid":false,"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CHU de Rennes, Universit\u00e9 de Rennes , Rennes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico","family":"Van de Veire","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Life Sciences, Vrije Universiteit Brussel , Brussels ,","place":["Belgium"]},{"name":"Department of Cardiology, AZ Maria Middelares , Gent ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-8503","authenticated-orcid":false,"given":"Philippe","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Oost-Limburg , Genk ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching Hui","family":"Sia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University Heart Centre , Singapore ,","place":["Singapore"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold C T","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Nabeta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center , Albinusdreef 2, Leiden 2333 ZA ,","place":["Netherlands"]},{"name":"Department of Cardiology, Kitasato University School of Medicine , Sagamihara ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Sturkenboom","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Antwerp , Antwerp ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idit","family":"Yedidya","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rabin Medical Center , Petah Tikva ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel Aviv University Department of Cardiology, , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-2612","authenticated-orcid":false,"given":"Ruxandra","family":"Jurcut","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases , Bucharest ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J","family":"Bax","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center , Albinusdreef 2, Leiden 2333 ZA ,","place":["Netherlands"]},{"name":"Department of Cardiology, Turku Heart Center, University of Turku and Turku University Hospital , Turku ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-5769","authenticated-orcid":false,"given":"Nina","family":"Ajmone Marsan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center , Albinusdreef 2, Leiden 2333 ZA ,","place":["Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026021112471002800_xvaf013-B1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021112471002800_xvaf013-B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021112471002800_xvaf013-B3","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026021112471002800_xvaf013-B4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021112471002800_xvaf013-B5","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021112471002800_xvaf013-B6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"2026021112471002800_xvaf013-B7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021112471002800_xvaf013-B8","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021112471002800_xvaf013-B9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021112471002800_xvaf013-B10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021112471002800_xvaf013-B11","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"2026021112471002800_xvaf013-B12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jchf.2014.12.017","article-title":"The hospitalization burden and post-hospitalization mortality risk in heart failure with preserved ejection fraction: results from the I-PRESERVE trial (irbesartan in heart failure and preserved ejection fraction)","volume":"3","author":"Carson","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026021112471002800_xvaf013-B13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021112471002800_xvaf013-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021112471002800_xvaf013-B15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"2026021112471002800_xvaf013-B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjci\/jeu184","article-title":"Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging","volume":"16","author":"Voigt","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021112471002800_xvaf013-B17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021112471002800_xvaf013-B18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjci\/jet105","article-title":"Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021112471002800_xvaf013-B19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021112471002800_xvaf013-B20","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy","volume":"11","author":"Garcia-Pavia","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021112471002800_xvaf013-B21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.cjca.2024.02.025","article-title":"The diagnostic and therapeutic implications of phenocopies and mimics of hypertrophic cardiomyopathy","volume":"40","author":"Bakalakos","year":"2024","journal-title":"Can J Cardiol"},{"key":"2026021112471002800_xvaf013-B22","doi-asserted-by":"publisher","first-page":"i40","DOI":"10.1093\/eurheartjsupp\/suae099","article-title":"From thick walls to clear answers: approaches to diagnosing hypertrophic cardiomyopathy and its mimics","volume":"27","author":"Angelini","year":"2025","journal-title":"Eur Heart J Suppl"},{"key":"2026021112471002800_xvaf013-B23","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021112471002800_xvaf013-B24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026021112471002800_xvaf013-B25","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021112471002800_xvaf013-B26","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026021112471002800_xvaf013-B27","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021112471002800_xvaf013-B28","doi-asserted-by":"publisher","first-page":"11g","DOI":"10.1016\/j.amjcard.2005.07.016","article-title":"Pathophysiologic targets in the early phase of acute heart failure syndromes","volume":"96","author":"Gheorghiade","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026021112471002800_xvaf013-B29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jacc.2024.10.097","article-title":"Worsening of heart failure in outpatients with transthyretin amyloidosis and cardiomyopathy in the APOLLO-B trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021112471002800_xvaf013-B30","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021112471002800_xvaf013-B31","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1002\/ehf2.14000","article-title":"Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis","volume":"9","author":"Ladefoged","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026021112471002800_xvaf013-B32","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021112471002800_xvaf013-B33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid"},{"key":"2026021112471002800_xvaf013-B34","doi-asserted-by":"publisher","first-page":"e022859","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026021112471002800_xvaf013-B35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/ehjcvp\/pvaf033","article-title":"Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies","volume":"11","author":"Laborante","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvaf013\/66269650\/xvaf013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvaf013\/66269650\/xvaf013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvaf013\/66269650\/xvaf013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:47:20Z","timestamp":1770832040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvaf013\/8414754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvaf013","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,8]]},"article-number":"xvaf013"}}